1Tadashi Iwao M.D.,Atsushi Toyonaga,Kyuichi Tanikawa. Gastric red spots in patients with cirrhosis: Subclinical condition of gastric mucosal hemorrhage?[J] 1990,Gastroenterologia Japonica(6):685～692
3Lopez-Talavera JC, Cadelina G, Olchowski J, et al. Thalidomide inhibits tumor necrosis factors alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats [ J]. Hepatology, 1996, 23(6) : 1616-1621.
4Groszmann R J, Vorobioff J, Riley E. Splanchnic hemodynamics in portal-hypertensive rats: measurement with gammalabeled microspheres [J]. Am J Physiol, 1982, 242(2): G156-G160.
5Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis [J]. Gut, 2006, 55 (S6): vi1-vi12.
6Geerts AM, De Vriese AS, Vanheule E, et al. Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an in vive study [ J]. Liver Int, 2006, 26 (7) : 889-898.
7Fernandez M, Vizzutti F, Garcia-Pagan JC, et al. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice [J]. Gastroenterology, 2004, 126(3) : 886-894.
8Fernandez M, Mejias M, Angermayr B, et al. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats [J]. J Hepatol, 2005, 43(1): 98-103.
9Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion : therapeutic applications [J]. Leukemia, 2001 (12), 15: 1950-1961.
10Sauer H, Gunther J, Hescheler J, et al. Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals [ J]. Am J Pathol, 2000, 156(1) :151-158.
